{"log_id": 3157942030521296522, "direction": 0, "words_result_num": 27, "words_result": [{"probability": {"variance": 0.001282, "average": 0.988527, "min": 0.786521}, "location": {"width": 832, "top": 185, "height": 47, "left": 205}, "words": "择性的DPP-4酶抑制剂,在达到治疗浓度时也不会抑制与DDP-4酶密切相关的"}, {"probability": {"variance": 0.014848, "average": 0.943527, "min": 0.529903}, "location": {"width": 184, "top": 248, "height": 27, "left": 207}, "words": "DPP-8或DPP-9酶海"}, {"probability": {"variance": 0.013629, "average": 0.942965, "min": 0.682254}, "location": {"width": 149, "top": 337, "height": 31, "left": 210}, "words": "盐酸二甲双胍"}, {"probability": {"variance": 0.000173, "average": 0.995708, "min": 0.922895}, "location": {"width": 828, "top": 371, "height": 46, "left": 211}, "words": "二甲双胍是一种降血糖药物,通过改善2型糖尿病患者的糖耐量来降低基础和餐"}, {"probability": {"variance": 0.000251, "average": 0.995268, "min": 0.904528}, "location": {"width": 829, "top": 420, "height": 44, "left": 211}, "words": "后血糖。它的药理学作用机理与其他口服降血糖药不同。二甲双胍可以减少肝脏"}, {"probability": {"variance": 3e-06, "average": 0.998773, "min": 0.993739}, "location": {"width": 831, "top": 468, "height": 44, "left": 211}, "words": "产生的葡萄糖、减少葡萄糖在肠道的吸收,还可以通过增加外周组织对葡萄糖的"}, {"probability": {"variance": 3.2e-05, "average": 0.996502, "min": 0.97982}, "location": {"width": 831, "top": 515, "height": 43, "left": 212}, "words": "摄入和利用来提高机体的胰岛素敏感度。与磺酰脲类药物不同的是,二甲双胍不"}, {"probability": {"variance": 0.001851, "average": 0.990358, "min": 0.741041}, "location": {"width": 827, "top": 561, "height": 45, "left": 214}, "words": "会引起2型糖尿病患者或健康人的低血糖(除非在特殊情况下,参见注意事项一"}, {"probability": {"variance": 0.004994, "average": 0.982296, "min": 0.575124}, "location": {"width": 828, "top": 608, "height": 46, "left": 217}, "words": "盐酸二甲双胍),也不会引起高胰岛素血症。患者接受二甲双胍治疗时体内胰岛"}, {"probability": {"variance": 1e-06, "average": 0.999104, "min": 0.995297}, "location": {"width": 789, "top": 657, "height": 43, "left": 217}, "words": "素的分泌量不变,但空腹胰岛素水平和白天的血胰岛素反应水平可能会降低"}, {"probability": {"variance": 1e-06, "average": 0.999389, "min": 0.997946}, "location": {"width": 123, "top": 758, "height": 29, "left": 219}, "words": "动物药理学"}, {"probability": {"variance": 0.000193, "average": 0.990912, "min": 0.96137}, "location": {"width": 147, "top": 806, "height": 27, "left": 222}, "words": "磷酸西格列汀"}, {"probability": {"variance": 0.039358, "average": 0.798257, "min": 0.599868}, "location": {"width": 89, "top": 814, "height": 37, "left": 833}, "words": "药经"}, {"probability": {"variance": 0.016358, "average": 0.942145, "min": 0.455123}, "location": {"width": 831, "top": 835, "height": 51, "left": 219}, "words": "研究者以瘦型小鼠和饮食诱导肥胖(D10)小鼠以及糖尿病(dbb6小鼠为研究"}, {"probability": {"variance": 0.011727, "average": 0.962418, "min": 0.485598}, "location": {"width": 829, "top": 886, "height": 45, "left": 221}, "words": "对象评价了西格列汀改善糖耐量的能力,其中瘦型小鼠和DIO小鼠接受了葡萄"}, {"probability": {"variance": 0.014164, "average": 0.941267, "min": 0.514425}, "location": {"width": 828, "top": 932, "height": 47, "left": 222}, "words": "糖负荷试验。瘦型小鼠和DIO小鼠口服单剂量西格列江以后血糖水平不降,且"}, {"probability": {"variance": 0.000441, "average": 0.992967, "min": 0.882663}, "location": {"width": 828, "top": 979, "height": 47, "left": 225}, "words": "下降幅度呈剂量依赖性。糖尿病dbdb小鼠服药后也会出现急性的血糖下降。瘦"}, {"probability": {"variance": 0.011792, "average": 0.959791, "min": 0.568891}, "location": {"width": 830, "top": 1026, "height": 48, "left": 223}, "words": "型小鼠口服最大有效剂量1mg/kg西格列汀后,体内的活性6LP-升高了2~3"}, {"probability": {"variance": 3.1e-05, "average": 0.998057, "min": 0.967272}, "location": {"width": 826, "top": 1076, "height": 43, "left": 224}, "words": "倍。上述动物试验结果与2型糖尿病患者临床试验结果是一致的,并与西格列汀"}, {"probability": {"variance": 5.2e-05, "average": 0.995485, "min": 0.977205}, "location": {"width": 195, "top": 1135, "height": 30, "left": 225}, "words": "的降血糖作用相符"}, {"probability": {"variance": 0.000888, "average": 0.993837, "min": 0.815436}, "location": {"width": 828, "top": 1210, "height": 46, "left": 228}, "words": "以啮齿类动物为研究对象的非临床试验表明,DPP-4抑制剂可能对胰腺β细胞的"}, {"probability": {"variance": 0.000816, "average": 0.989756, "min": 0.86973}, "location": {"width": 801, "top": 1257, "height": 47, "left": 230}, "words": "功能有益处。用GLP-1或DPP4抑制剂治疗2型糖尿病动物模型的结果表明"}, {"probability": {"variance": 0.002756, "average": 0.984841, "min": 0.696707}, "location": {"width": 829, "top": 1304, "height": 48, "left": 228}, "words": "GLP-1或DPP-4抑制剂可以改善β细胞对血糖的反应,刺激胰岛素的生物合成"}, {"probability": {"variance": 0.007794, "average": 0.979423, "min": 0.478215}, "location": {"width": 826, "top": 1351, "height": 47, "left": 231}, "words": "和释放,促进β细胞的再生并减少β细胞的死亡。一种结构上与西格列汀相似"}, {"probability": {"variance": 0.000682, "average": 0.991477, "min": 0.868829}, "location": {"width": 828, "top": 1399, "height": 45, "left": 231}, "words": "的选择性DPP-4抑制剂治疗2型糖尿病小鼠模型的研究也证实,DDP-4抑制剂"}, {"probability": {"variance": 0.015198, "average": 0.960034, "min": 0.492035}, "location": {"width": 825, "top": 1446, "height": 44, "left": 233}, "words": "治疗可以促进β-细胞的再生并升高胰岛素产生β-细胞与胰高血糖素产生a细胞"}, {"probability": {"variance": 0.001776, "average": 0.988734, "min": 0.754231}, "location": {"width": 765, "top": 1492, "height": 46, "left": 234}, "words": "的比率。目前还没有开展人类试验研究药物对β-细胞的新生和死亡的影响"}], "language": 3}